Cancer nanomedicine: from targeted delivery to combination therapy

被引：691

作者：

Xu, Xiaoyang ^{[1
,2
,3
]}

Ho, William ^{[1
]}

Zhang, Xueqing ^{[1
]}

Bertrand, Nicolas ^{[1
,2
]}

Farokhzad, Omid ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Lab Nanomed & Biomat, Boston, MA 02115 USA

[2] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA

[3] New Jersey Inst Technol, Dept Chem Biol & Pharmaceut Engn, Newark, NJ 07102 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2015年 / 21卷 / 04期

基金：

加拿大健康研究院; 美国国家卫生研究院;

关键词：

nanomedicine; targeted delivery; combination therapy; cancer; DRUG-DELIVERY; POLYMERIC NANOPARTICLES; ZWITTERIONIC POLYMER; SIRNA; TUMOR; NANOTECHNOLOGY; CISPLATIN; SIZE; NANOMATERIALS; THERAPEUTICS;

D O I：

10.1016/j.molmed.2015.01.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer. The unique properties of nanoparticles (NPs), such as large surface-to-volume ratio, small size, the ability to encapsulate various drugs, and tunable surface chemistry, give them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies. This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy.

引用

页码：223 / 232

页数：10

共 79 条

[1]

PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect [J].